Vir Biotech Q3 net loss $163M ($1.17/sh); ECLIPSE enrollment ahead of schedule

Vir Biotechnology, Inc.

2025-Q3 EPS reported -$2.86 revenue$4,486,000

Net loss $163.1M ($1.17/sh) vs $213.7M ($1.56) in Q3 2024; revenues $0.2M.
Cash and investments $810.7M as of Sept 30, 2025; runway into mid-2027.
ECLIPSE 1 enrollment completed ~2 months early; topline data for all three HDV studies expected Q1 2027.
VIR-5500 first patient dosed in combo with ARPIs in 1L mCRPC; comprehensive data update planned Q1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.